Essentials
• The role of von Willebrand factor (VWF) domains in regulating platelet adhesion was studied in vivo.
• Multimeric VWF with spacers at the N-and C-terminus of VWF-A1 were systematically tested.
• N-terminal modified VWF avidly bound platelet GpIba, causing VWD Type2B like phenotype in mice.
• Novel anti-D'D3 mAbs suggest that changes at the D'D3-A1 interface may be biologically relevant.
Summary. Background: Previous ex vivo studies using truncated VWF (von Willebrand factor) suggest that domain-level molecular architecture may control plateletGpIba binding function. Objective: We determined if this is the case with multimeric VWF in vivo. Methods: Fulllength human VWF ('hV') was modified with a 22-amino acid mucinous stretch at either the N-terminus of VWF-A1 to create 'hNV' or C-terminus to yield 'hCV'. This extends the physical distance between VWF-A1 and the adjacent domains by~6 nm. Similar mucin inserts were also introduced into a human-murine chimera ('h[mA1] V') where murine-A1 replaced human-A1 in hV. This yielded 'h[mA1]NV' and 'h[mA1]CV', with N-and Cterminal inserts. The constructs were tested ex vivo and in vivo. Results: Mucin insertion at the N-terminus, but not C-terminus, in both types of constructs resulted in >50-fold increase in binding to immobilized GpIba. Nterminal insertion also resulted in greater shear-induced platelet activation, more thrombus formation on collagen, enhanced platelet accumulation and slower platelet translocation on immobilized VWF in microfluidics assays.
Hydrodynamic injection-based expression of h[mA1]NV, but not h[mA1]V or h[mA1]CV, in VWF
Introduction von Willebrand factor (VWF) is a large, multimeric plasma glycoprotein that is secreted into circulation from endothelial cells, platelets and megakaryocytes [1, 2] . It contains a globular, compact head-structure with the D'D3-A1-A2-A3-D4 domains, followed by an extended arm that contains six C-type domains and the cysteine knot [3, 4] . The A1 domain of VWF regulates thrombosis and hemostasis in part by binding platelet GpIba under fluid shear [5, 6] . A number of ex vivo studies using truncated VWF mutants show that the structural domains adjacent to A1, particularly the D'D3 and A2 domains, regulate the rates of platelet binding [7] [8] [9] [10] . Such domain-level interactions may be important because the VWF-A1 crystal structure itself is not very different (root mean square deviation < 2 A) between wild-type A1 and von Willebrand disease (VWD) mutants that display altered A1-GpIba binding affinity [11] . The most profound change noted here relates to the position of the VWF-A1 N-terminal (amino acids/aa 1261-1271) and C-terminal (aa 1459-1468) peptides [12, 13] . These peptides are proximal to the b-finger binding region in the unliganded A1 domain but are displaced in the VWF-A1 co-crystal with GpIba [13] .
Consistent with the notion that structural features Nterminus to VWF-A1 regulate GpIba binding, a dimeric protein containing A1-CK binds GpIba better than another dimeric protein containing D'D3 [9] . This implies that the D'D3 domain may shield A1-GpIba binding. Additionally, the binding of the VWF propeptide to VWF-D'D3 hinders functional A1-GpIba interactions [14] , with D'D3 domain deletion enhancing this molecular binding [8] . Deletion of the 'N-terminal flanking peptide' of VWF-A1 (amino acid/aa 1238-1260) also enhances platelet binding, particularly in assays where VWF is immobilized on plastic or collagen [8, 15] . Modifying the O-glycans also reduces platelet adhesion [16] . In addition to the features at the N-terminal, the A2 domain located at the C-terminus has also been implicated in binding VWF-A1 in surface plasmon resonance studies [10] , and molecular dynamic simulations suggest that VWF-A2 may reduce GpIba-A1 binding [17] . The above studies have limitations: (i) They rely on VWF deletion mutations, rather than the full multimeric protein.
(ii) They focus individually on structural features at either the Nor C-terminal alone, and thus a systematic side-by-side comparison of the relative impact of the D'D3 and A2 domains in regulating A1-GpIba binding remains unknown. (iii) They rely on in vitro measurements, and thus the role of domain-level interactions in controlling bleeding and thrombosis in the more complex in vivo physiological milieu remains undetermined.
To address these shortcomings, the current study minimally perturbed human VWF by introducing a short 22 amino acid peptide from human CD43 as a physical spacer, at either the N-or C-terminus of VWF-A1 in multimeric VWF. This insert has 10 putative O-glycosylation sites and thus it is expected to act as a stiff spacer that extends the physical distance between VWF-A1 and either D'D3 or A2 domains by up to~6 nm (3 A/residue) [18, 19] . In vitro and in vivo functional studies suggest that structural features N-terminus to the A1-domain, but not the C-terminus, is the major feature regulating platelet adhesion and thrombosis. Hydrodynamic injection of the VWF construct with the N-terminal spacer (between D'D3 and A1) into mice resulted in profound thrombocytopenia and bleeding diathesis that resembles VWD type 2B. A screen of several anti-D'D3 mAbs identified a clone DD3.3, which displays higher binding to VWF protein with N-terminal spacer. The binding of mAb DD3.3 to VWF was augmented by hydrodynamic shear and ristocetin, suggesting that structural changes at the D'D3-A1 interface may be physiologically relevant and may contribute to 'VWF activation'.
Material and methods

Materials
Function-blocking mouse anti-human IgGs used include the anti-VWF-A1 mAb AVW-3 (GTI Diagnostics, Milwaukee, WI, USA) and anti-GpIba clone AK2 (Millipore, Burlington, MA, USA), both of which inhibit A1-GpIba binding. The anti-VWF-D'D3 mAb DD3.1 blocks both VWF-propeptide binding to mature VWF and A1-GpIba interactions [14] . Additional anti-D'D3 mAbs were produced by immunizing BALB/c mice with human D'D3 [14] .
To create recombinant VWF, wild-type human VWF ('hV') in pCDNA3.1 vector was used as a starting material [4] . Complementary oligos encoding for 22 amino acids (ESTSEPLSSKMYTTSITSDPKI/V) of the mucinrich repeat of CD43 were annealed and inserted either just after aa1263 in VWF-A1 in 'hV' (at the D'D3 interface, after the 'N-terminal flanking peptide') or following aa1476 (between A1 and A2) [4] . The resulting proteins with N-and C-terminal inserts are called 'hNV' and 'hCV', respectively. Additionally, for some studies, the CD43-insert was also placed following aa1238 (before the 'N-terminal flanking peptide') to yield hNV [1238] , and aa1458 to obtain hCV [1458] . A human-murine chimeric VWF where the murine-A1 domain replaced human VWF-A1 ('h[mA1]V') was also cloned into the pLive vector (Mirus-Bio, Madison, WI, USA). Insertion of the CD43 mucin peptide at the N-(after aa1263) and C-terminus (after aa1476) of [mA1] in this vector yielded 'h [mA1]NV' and 'h[mA1]CV'. All proteins were expressed by transient transfection of HEK-293T cells overexpressing furin in serum-free media [20] , and concentrated 50-100-fold to 200-400 lg mL À1 for functional studies.
Human subject protocols were approved by the UB Health Science Institutional Review Board, and animal protocols were approved by the UB Institutional Animal Care and Use Committee.
Concentration determination and western blotting
VWF concentration was determined with a flow cytometer-bead sandwich assay, using multimeric VWF purified from humate-P (CSL Behring) as a standard [4] . Humanmurine VWF chimera levels in mouse plasma were determined using calibration curves generated by spiking VWF À/À mouse plasma with human plasma pooled from five normal adult volunteers. VWF multimer distribution was assayed using 0.6-1.2% agarose gel electrophoresis [21] . To assay VWF susceptibility to proteolysis by ADAMTS-13, 10 lg mL À1 VWF was incubated with 10 U mL À1 ADAMTS-13
(WHO standard) and 1.6 M urea at 37°C for 24 h. Western blotting of cleaved VWF products was assayed under standard reducing conditions using 4-8% SDS-PAGE followed by detection using anti-VWF Ab (Dako A/S, Glostrup, Denmark).
Functional assays
Washed platelets were prepared as described earlier [14, 20] . The apparent dissociation constant (K D ) of VWFGpIba binding was measured using ELISA [8] . Here, K D measures the avidity of multimeric VWF binding to GpIba-Fc immobilized at~100 sites lm À2 . Shear-induced platelet activation (SIPAct) was measured using a coneplate viscometer to apply shear and annexin-V to quantify cell activation [20] . Platelet accumulation (bound cells mm À2 ) and cell translocation velocity (lm s À1 ) were measured on substrates bearing VWF using a microfluidic flow cell [8, 22] . Thrombus formation (% surface area coverage and fluorescence intensity) was measured on 20 lg mL À1 equine collagen type-I using a microfluidics assay [8] . Here, bead-bound DD3.5 was quantified after shear stoppage, using a secondary anti-mouse Alexa 647 Ab.
Mouse studies
Fifty lg of VWF cDNA in pLive vector were hydrodynamically injected into the tail vein of 8-12-week-old VWF À/À mice of either sex using a 26-gauge needle. The injection volume was 0.1 mL DNA in sterile PBS/g mouse and injection time was~5 s [23, 24] . Blood was collected at various times thereafter using retro-orbital bleeds for measurement of: (i) complete blood count, (ii) plasma VWF levels using the cytometer-bead assay, (iii) bilirubin, based on plasma 450 nm absorbance with respect to a standard curve generated by diluting bilirubin (Sigma-Aldrich, St Louis, MO, USA) into VWF À/À plasma, and/or (iv) flow cytometry-based platelet counts. All mouse tail-bleed assays were performed at 48 h. Here, mice anesthetized using isoflurane were placed in a restraining device; 4 mm of the distal tail was cut off using a sharp scalpel, and the amputated tail was quickly immersed in a pre-weighed tube containing physiological saline at 37°C. Bleeding time was measured from the moment of transection until first arrest of bleeding.
Observations were stopped at 30 min when bleeding did not cease. The bleeding volume was obtained from the change in weight of the pre-weighed tube. Standard paraffin-embedded H&E, trichrome staining and immunohistochemistry were performed. In some runs, to stain for VWF expression and platelet thrombi, the rodent was perfusion-fixed at 48 h [25] . These sections were stained with 1 : 100 rhodamine-conjugated wheat germ agglutinin for cell membrane, 1 : 1000 DyLight-488 conjugated anti-platelet Ab (#X488, Emfret Analytics, Eibelstadt, Germany) and 1 : 100 anti-VWF Ab (Dako), followed by secondary goat anti-rabbit Alexa 647 Ab to detect chimeric VWF. Images were acquired using a Zeiss LSM510 meta NLO scanning confocal microscope (40X/ 0.55 N.A objective).
Statistics
All data are presented as mean AE SD for > three independent experiments. Student's two-tailed t-test was performed for dual comparison. One-way analysis of variance (ANOVA) followed by the Tukey post-test was performed for multiple comparisons. P < 0.05 was considered significant.
Results
Mucin insert at the N-, but not C-, terminus of VWF-A1 augments binding to GpIba
The 22aa CD43 mucin insert was placed at the N-terminus of the A1 domain to create hNV or C-terminus to create hCV (Fig. 1A) . When resolved using SDS-agarose gel, hV and hCV had a comparable multimer distribution, with hNV tending to produce smaller units (Fig. 1B) . Under reducing conditions, the molecular mass of hNV and hCV monomers was~12 kDa greater than that of hV, consistent with the notion that the mucin insert is extensively glycosylated (Fig. 1C) . Here, the 22aa themselves contribute 2 kDa to the mass, with each additional O-glycan adding~1 kDa, as these are commonly either disialylated T-antigen (Neu5Aca2-3Galb1-3[Neu5Aca2-6] GalNAca) or core-2 (Neu5Aca2-3Galb1-3[Neu5Aca2-3Galb1-4GlcNAcb1-6]GalNAca) structures. Increased glycosylation in mucin-modified VWF (hNV and hCV) was also evident in a peanut agglutinin binding assay ( Figure S1 ). Incubation of the constructs with ADAMTS-13 for 24 h in the presence of urea revealed that hCV was somewhat less susceptible to proteolysis compared to hNV and hV. Thus, the C-terminal mucin may partially inhibit A2-domain cleavage (Fig. 1D) .
Static microtiter plate studies measured soluble VWF binding to immobilized GpIba-Fc. Here, hNV displayed higher binding for immobilized GpIba (K D,app~0 .37 lg mL
À1
) compared with hV and hCV (Fig. 1E ). hV and hCV binding affinity did not reach saturation up to 40 lg mL À1 . Thus, increasing the physical spacing between the D'D3 and A1 domains dramatically decreased the apparent dissociation constant (K D ) by > 100-fold. The binding of all VWF variants to immobilized GpIba was specific and could be blocked by mAbs against either GpIba (AK2) or the VWF A1 domain (AVW-3) (Fig. 1F ). The anti-D'D3 mAb DD3.1 blocked hV and hCV binding to GpIba but had no effect on hNV-GpIba binding. Increasing the spacing between D'D3 and A1 may prevent steric mAb blocking observed with wild-type VWF. Mucin insertion between VWF-A1 and VWF-A2 in hCV had no effect on DD3.1 inhibition.
Upon ristocetin addition, all constructs bound GpIba equally well (Fig. 1G) . Although blocking mAbs against GpIba and VWF-A1 were effective, the anti-D'D3 mAb DD3.1 was now ineffective. Overall, mucin insertion between D'D3 and A1 released steric blocking by VWF-D'D3, thus promoting A1-GpIba binding.
N-terminal mucin insert enhances platelet activation
We determined if N-terminal mucin insertion enhances platelet activation in the SIPAct assay by promoting VWF-GpIba binding. Here, washed human platelets were shear mixed with the different recombinant VWF variants at 9600/s in a cone-plate viscometer. Annexin-V binding to platelets was used as a marker of cell activation (Fig. 2) . Here, hNV triggered more rapid and higher platelet activation compared with hV or hCV ( Fig. 2A) , with 80% platelet activation being observed within 60 s. Whereas DD3.1 inhibited SIPAct triggered by hV or hCV by~70% (Fig. 2B, 2D ), this mAb did not reduce platelet activation triggered by hNV (Fig. 2C) . Blocking mAbs against GpIba and VWF-A1 abolished SIPAct in all cases (Fig. 2E) . hNV increased SIPAct without altering the critical shear threshold required for platelet activation (Figure S2 ). This is consistent with the notion that SIPAct is a two-step process, with VWF-GpIba binding being separable from subsequent mechanotransduction [21] . Overall, the physical spacing between D'D3 and A1 is a critical determinant for solution-based platelet activation.
VWF-D'D3 regulates thrombus formation and platelet translocation
Thrombus formation on fibrillar collagen was measured using microfluidic flow chambers in order to determine the effects of VWF domains in regulating platelet adhesion in models of vascular injury (Fig. 3A, 3B) . Here, fluorescent human washed platelets supplemented with erythrocytes at physiological hematocrit and 10 lg mL À1 recombinant human VWF variants were perfused over collagen at a wall shear rate of 1000/s (shear stress 40 dyn cm À2 ). Here, compared with hV (wild-type) and hCV, hNV contributed to more extensive platelet thrombosis (Fig. 3A) and larger contiguous thrombi (Fig. 3B) . Platelet deposition was negligible in controls lacking recombinant VWF. All VWF variants bound collagen equally. Thus, the mutations do not affect VWF-collagen binding ( Figure S3 ). The platelet translocation assay measured washed human platelet accumulation (Fig. 3C ) and translocation velocity (Fig. 3D) at a wall stress of 3 dyn cm À2 , on substrates that had physisorbed hV, hCV or hNV. Equivalent amounts of VWF were immobilized in all cases.
Here, significantly higher platelet accumulation (Fig. 3C ) and lower translocation velocity (Fig. 3D) were observed on hNV compared with other constructs. Platelet adhesion was specifically blocked by mAbs against GpIba and VWF-A1, with anti-D'D3 mAb DD3.1 only reducing adhesion on hV and hCV (Fig. 3E) .
Similar observations to those with hNV and hCV were made using constructs where the mucin insert was placed at aa1238 at the N-terminus (hNV [1238] ) and aa1458 at the C-terminus (hCV[1458]) ( Figure S4 ). Thus, all data support the notion that VWF-D'D3 is the dominant regulator of A1-GpIba binding in both solution (Fig. 2 ) and substrate assays (Fig. 3) . The A2 domain had a small effect, relative to VWF-D'D3.
N-terminal spacing augments chimeric-VWF GpIba binding
Because murine GpIba does not bind human VWF [26] , chimeric VWF constructs were created for in vivo studies (Fig. 4A) . Here, h[mA1]V is identical to human VWF (hV), except that the human-A1 is replaced by murine-A1.
Insertion of the CD43 spacer at the N-or C-terminus of the mA1 domain resulted in h[mA1]NV and h[mA1]CV. h[mA1]V, h[mA1]NV and h[mA1]
CV were functionally similar to hV, hNV and hCV, respectively (Fig. 4B-F) . All proteins were expressed well in HEK293Ts, with h[mA1]NV displaying slightly smaller multimers (Fig. 4B) . A~12 kDa increase in monomer mass was noted for h[mA1]NV and h[mA1]CV with respect to h [mA1]V (Fig. 4C) . In microtiter assays, h[mA1]NV binding to GpIba exhibited an apparent K D of 0.31 lg mL À1 , similar to hNV (Fig. 4D vs. Fig. 1E (Fig. 4E ). In the presence of ristocetin, all VWF variants displayed high binding to GpIba, which could be blocked by anti-GpIba mAb but not DD3.1 ( Figure S5 ). In the thrombus formation assay also, N-terminal mucin insertion enhanced thrombus formation ( 
Hydrodynamic injection of h[mA1]NV into mice causes thrombocytopenia resembling VWD type 2B
Bleeding and thrombosis is complex in vivo because many different blood proteins interact with VWF and the hemodynamics is also heterogeneous [1] . To determine if domain-level structural features control VWF function in vivo, pLive vectors encoding for different chimeric proteins were hydrodynamically injected into VWF À/À mice (Fig. 5) . Forty-eight hours post-injection, profound thrombocytopenia was evident in h[mA1]NV-expressing mice, with 70-90% reduction in platelet count (Fig. 5A) . (Fig. 5B, Figure S7 ). The extent of bleeding was greater in the h[mA1]NV-injected mice compared with PBS controls, although the difference did not reach statistical significance. Although h[mA1]V-expressing mice had plasma VWF concentrations at~80% of that of pooled human plasma, this was reduced to~25% in the h[mA1]NV mice (Fig. 5C ). The h[mA1]NV mice also lacked larger VWF multimers (Fig. 5D) /lL) or bleeding time (~5 min), with plasma VWF levels remaining comparable to those in humans (data not shown). Immunohistochemical analysis revealed that VWF was expressed in hepatocytes at similar levels in both h[mA1] NV and h[mA1]V animals (Fig. 5E) . The proteins were also expressed in the lung ( Figure S8 ) but not other organs examined using immunohistochemistry (brain, spleen, kidney and heart). Platelet-rich thrombi were commonly observed in the portal veins and hepatic arteries of the h [mA1]NV mice (Fig. 5E, Figure S9 ), and this may account for the thrombocytopenia. Intravascular thrombi were not observed in other organs. Trichrome-stained sections did not reveal differences in interstitial and perivascular collagen deposition in h[mA1]NV mice compared with controls (data not shown). Plasma bilirubin levels remained unchanged following h[mA1]NV expression ( Figure S6 ). Overall, D'D3 critically regulates VWF adhesive function in vivo by tuning A1-GpIba binding. Hydrodynamic injection of h[mA1]NV into VWF À/À mice results in VWD type 2B-like symptoms with reduced plasma VWF expression, lower protein multimer distribution and profound thrombocytopenia [27] . Additionally, the introduction of this hyper-adhesive VWF form did not cause histologic abnormalities detectable under light microscopic examination.
Fluid shear and ristocetin may alter the structure of the D'D3-A1 interface
To determine if the physical spacing between VWF-A1 and VWF-D'D3 may change under physiological shear, we screened a panel of anti-D'D3 IgG mAbs to identify entities that display greater binding to hNV compared with hV or hCV ( Figure S10 ). These studies identified mAb DD3.3 as a reagent displaying 1.5-2-fold greater binding to hNV compared with the other constructs. MAb DD3.5 served as a control as it did not bind differentially to the VWF proteins. When ristocetin was added in ELISA, DD3.3 binding was increased for all VWF constructs by 3-7-fold (Fig. 6A) , with no change noted for DD3.5 (Fig. 6B) . When wild-type VWF (hV) immobilized on anti-VWF Ab bearing beads was subjected to hydrodynamic shear in a cone-plate viscometer, also, mAb DD3.3 binding to beads increased progressively with an applied shear rate > 2400 s À1 (Fig. 6C) . No shear-dependent change in DD3.5 binding was observed (Fig. 6D) . Thus, DD3.3 is a novel anti-D'D3 conformational sensitive mAb that preferentially binds the active form of VWF. Further, the data suggest that domainlevel structural changes may occur at the VWF D'D3-A1 interface upon physiological fluid flow application and ristocetin addition.
Discussion
This manuscript shows that mucin spacer insertion between the VWF D'D3 and A1 domains enhances VWF binding to platelet GpIba in a variety of settings. This increased spacing augments platelet binding to VWF, and also thrombus formation on collagen under physiological flow. Platelet recruitment was also augmented on VWF substrates and platelet translocation velocity was decreased. We chose the O-glycan cluster to increase the physical separation between domains in this study, because this results in a stiff spacer unlike the classic Gly-Ser linker, which is flexible [28] . Insertion of the mucin spacer at either aa1263 (after the 'N-terminal flanking peptide' [7, 29, 30] ) or aa1238 (before the 'flanking peptide') at the N-terminal of VWF-A1 had a similar biological function. Thus, the 'flanking peptide' may not contribute to A1-domain function in the context of multimeric VWF. In contrast to the N-terminal insertion, similar changes at the C-terminus at the A1-A2 interface (at either aa1476 or aa1458) only marginally affected VWF function, with a slight decrease in ADAMTS-13 proteolysis rates and a small effect on thrombus formation on collagen. Indeed, others have previously suggested that the A2 domain may bind VWF-A1 and reduce its ability to engage GpIba [10] . Although this may be true in some settings, based on our systematic side-by-side comparison of multimeric VWF, it is more likely that the physical spacing between D'D3 and A1 is the critical regulator of A1-GpIba binding rates under physiological conditions.
To ensure that the conclusions of this work are not artifacts due to mucin insertion, we tested the effect of mucin insertion at multiple locations at the N-terminus and C-terminus. We also screened a panel of mAbs against the VWF-D'D3 domain and applied them in studies with wildtype VWF. These studies revealed a non-function blocking mAb DD3.3 ( Figure S11 ), whose binding to VWF was augmented in the presence of ristocetin and also hydrodynamic shear. In this regard, ristocetin binds aa1237-1266 and aa1458-1472 at the N-and C-terminus of VWF-A1 [31] , and this binding interaction is not abolished in our mutants. Based on observations that DD3.3 binding is enhanced by ristocetin, the data suggest that ristocetin may promote structural rearrangements at the A1-D'D3 interface in addition to promoting VWF-GpIba binding. Besides DD3.3, the function-blocking mAb DD3.1 inhibited VWF-GpIba binding when D'D3 and A1 were proximal to each other both in native hV and h[mA1]V, but it was ineffective when the D'D3-A1 distance was increased using the spacer in hNV and h[mA1]NV. DD3.1 was also ineffective upon addition of ristocetin. Together, the data using the two mAbs support the notion that the physical distance between D'D3 and A1 may be altered when VWF undergoes shear-induced conformation changes (Fig. 7,  [32] ). The detailed mapping of the mAb binding sites on D'D3 is awaited as this may reveal the protein structure at the D'D3-A1 interface. Others have also demonstrated enhanced binding of single domain VWD type 2B mutants (e.g. I546V) to platelet GpIba under shear [33] . More studies are needed to determine if structural changes at the D'D3-A1 interface accompany VWF binding to collagen, and the relative importance of this during VWD type 2B disease where single nucleotide polymorphisms located away from the A1-GpIba binding interface augment VWFplatelet adhesion interactions [1, 2, 6] .
Besides basic science, the findings highlighted in this manuscript may be of translational significance. In this regard, the mucin insertion between VWF-D'D3 and VWF-A1 in multimeric VWF significantly augmented platelet activation in solution-based assays where VWF was sheared with platelets at 100 dyn cm À2 in a cone-plate viscometer. This structural change also decreased the apparent K D of VWF-GpIba binding by > 50-100-fold. Based on these dramatic effects, it is possible that the physical separation between D'D3 and A1 may control platelet function under high shear conditions, as observed in stenosed arteries and prosthetic devices such as heart valves, ECMOs (extracorporeal membrane oxygenation) and LVADs (left ventricular assist devices) [34, 35] . In vivo, the chimeric VWF protein h[mA1]V largely restored the homeostatic defect in VWF À/À mice. VWF expression levels in these animals, 2 days following hydrodynamic injection, were comparable to those in humans and blood platelet counts were normal. NV may be due to its higher affinity binding to murine platelet GpIba, which results in faster protein clearance, especially for the higher multimers. The dramatic loss of platelets from circulation may also be due to the enhanced clearance of VWFinduced activated platelets and thrombi in the liver. These observations are similar to previous work that used hydrodynamic injection to create VWD type 2B in mice [36, 37] , although platelet depletion is more robust in this work. Additionally, because of the nature of the construct design, there is no need to wait for several weeks to allow VWF levels to stabilize when using our vectors as protein levels are already close to those of humans within 2-3 days [38] . In summary, the spatial proximity between VWF D'D3 and A1 is likely to be a critical feature regulating VWF binding to GpIba in shear-based ex vivo studies and in vivo. This may be a key structural feature controlling thrombosis and hemostasis in man. Fig. S4 . Functional studies with human VWF containing mucin-inserts following aa1238 at the N-terminus of VWF-A1 and aa1458 at the C-terminus of A1. Fig. S5 . Chimeric VWF binding to GpIba in the presence of ristocetin. Fig. S6 . Time course of VWF expression and platelet counts following h[mA1]NV hydrodynamic injection. Fig. S7 . Tail bleeding time. Fig. S8 . Immunohistochemical staining of lung section. Fig. S9 . VWF expression and platelet thrombosis in liver. Fig. S10 . Conformational sensitive mAb screening. Fig. S11. DD3.3 is a non-function blocking mAb.
